Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

profileAmanda J Redig, M.D., Ph.D.

TitleInstructor in Medicine
InstitutionDana-Farber Cancer Institute
DepartmentMedicine
AddressDana-Farber Cancer Institute
Lc-4116
450 Brookline Ave
Boston MA 02215
Phone617/632-6036
Fax617/582-7683
vCardDownload vCard (login for email)

Collapse Research 
Collapse research activities and funding
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
F30ES015668     (REDIG, AMANDA J)May 1, 2007 - Apr 30, 2011
NIH/NIEHS
The Protein Kinase C Pathway In Acute Leukemia
Role: Principal Investigator

Collapse Bibliographic 
Collapse selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Krall EB, Wang B, Munoz DM, Ilic N, Raghavan S, Niederst MJ, Yu K, Ruddy DA, Aguirre AJ, Kim JW, Redig AJ, Gainor JF, Williams JA, Asara JM, Doench JG, Janne PA, Shaw AT, McDonald Iii RE, Engelman JA, Stegmeier F, Schlabach MR, Hahn WC. KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer. Elife. 2017 Feb 01; 6. PMID: 28145866.
    View in: PubMed
  2. Redig AJ, Costa DB, Taibi M, Boucher D, Johnson BE, Jänne PA, Jackman DM. Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotinib in a Phase 2 Trial. JAMA Oncol. 2016 Sep 01; 2(9):1240-2. PMID: 27387964.
    View in: PubMed
  3. Sahai V, Redig AJ, Collier KA, Eckerdt FD, Munshi HG. Targeting BET bromodomain proteins in solid tumors. Oncotarget. 2016 08 16; 7(33):53997-54009. PMID: 27283767.
    View in: PubMed
  4. Yanagita M, Redig AJ, Paweletz CP, Dahlberg SE, O'Connell A, Feeney N, Taibi M, Boucher D, Oxnard GR, Johnson BE, Costa DB, Jackman DM, Jänne PA. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial. Clin Cancer Res. 2016 Dec 15; 22(24):6010-6020. PMID: 27281561.
    View in: PubMed
  5. Redig AJ, Jänne PA. No Target Left Behind: Improving Therapeutic Options for ERBB2-Mutant Non-Small Cell Lung Cancer. J Thorac Oncol. 2016 Jun; 11(6):784-6. PMID: 27211578.
    View in: PubMed
  6. Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H, Jones RE, Kulkarni MM, Kuraguchi M, Palakurthi S, Fecci PE, Johnson BE, Janne PA, Engelman JA, Gangadharan SP, Costa DB, Freeman GJ, Bueno R, Hodi FS, Dranoff G, Wong KK, Hammerman PS. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016 Feb 17; 7:10501. PMID: 26883990; PMCID: PMC4757784.
  7. Redig AJ, Capelletti M, Dahlberg SE, Sholl LM, Mach S, Fontes C, Shi Y, Chalasani P, Jänne PA. Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer. Clin Cancer Res. 2016 Jul 01; 22(13):3148-56. PMID: 26861459.
    View in: PubMed
  8. Redig AJ, Jänne PA. Basket trials and the evolution of clinical trial design in an era of genomic medicine. J Clin Oncol. 2015 Mar 20; 33(9):975-7. PMID: 25667288.
    View in: PubMed
  9. Redig AJ, Vaidya A, Price C, Katz JT, Maguire JH. Interactive medical case. A chilly fever. N Engl J Med. 2014 Oct 16; 371(16):e24. PMID: 25317891.
    View in: PubMed
  10. Redig AJ, McAllister SS. Breast cancer as a systemic disease: a view of metastasis. J Intern Med. 2013 Aug; 274(2):113-26. PMID: 23844915; PMCID: PMC3711134.
  11. Redig AJ, Vaidya A, Bienfang DC, Milligan T. Interactive medical case. A pain in the brain. N Engl J Med. 2013 Apr 11; 368(15):e20. PMID: 23574142.
    View in: PubMed
  12. Redig AJ, Berliner N. Pathogenesis and clinical implications of HIV-related anemia in 2013. Hematology Am Soc Hematol Educ Program. 2013; 2013:377-81. PMID: 24319207.
    View in: PubMed
  13. Shields MA, Dangi-Garimella S, Redig AJ, Munshi HG. Biochemical role of the collagen-rich tumour microenvironment in pancreatic cancer progression. Biochem J. 2012 Jan 15; 441(2):541-52. PMID: 22187935.
    View in: PubMed
  14. Redig AJ. A piece of my mind. The patient's patients. JAMA. 2011 Jul 20; 306(3):247-8. PMID: 21771979.
    View in: PubMed
  15. Altman JK, Sassano A, Kaur S, Glaser H, Kroczynska B, Redig AJ, Russo S, Barr S, Platanias LC. Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors. Clin Cancer Res. 2011 Jul 01; 17(13):4378-88. PMID: 21415215; PMCID: PMC3131493.
  16. Redig AJ, Vakana E, Platanias LC. Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR-ABL. Leuk Lymphoma. 2011 Feb; 52 Suppl 1:45-53. PMID: 21299459.
    View in: PubMed
  17. Redig AJ. The monsters of medicine: Political violence and the physician. Pharos Alpha Omega Alpha Honor Med Soc. 2011; 74(1):16-22. PMID: 21384793.
    View in: PubMed
  18. Redig AJ, Brannigan R, Stryker SJ, Woodruff TK, Jeruss JS. Incorporating fertility preservation into the care of young oncology patients. Cancer. 2011 Jan 01; 117(1):4-10. PMID: 21235031; PMCID: PMC3057679.
  19. Redig AJ, Munshi HG. Metabolic syndrome after hormone-modifying therapy: risks associated with antineoplastic therapy. Oncology (Williston Park). 2010 Aug; 24(9):839-44. PMID: 20923040.
    View in: PubMed
  20. Dangi-Garimella S, Redig AJ, Shields MA, Siddiqui MA, Munshi HG. Rho-ROCK-myosin signaling mediates membrane type 1 matrix metalloproteinase-induced cellular aggregation of keratinocytes. J Biol Chem. 2010 Sep 03; 285(36):28363-72. PMID: 20605790; PMCID: PMC2934700.
  21. Redig AJ, Munshi HG. Care of the cancer survivor: metabolic syndrome after hormone-modifying therapy. Am J Med. 2010 Jan; 123(1):87.e1-6. PMID: 20102997; PMCID: PMC2821047.
  22. Redig AJ. Adventures in (health-insurance-claim) wonderland. Health Aff (Millwood). 2009 Sep-Oct; 28(5):1515-20. PMID: 19738271.
    View in: PubMed
  23. Joshi S, Kaur S, Redig AJ, Goldsborough K, David K, Ueda T, Watanabe-Fukunaga R, Baker DP, Fish EN, Fukunaga R, Platanias LC. Type I interferon (IFN)-dependent activation of Mnk1 and its role in the generation of growth inhibitory responses. Proc Natl Acad Sci U S A. 2009 Jul 21; 106(29):12097-102. PMID: 19574459; PMCID: PMC2715502.
  24. Redig AJ. In search of sleep. Acad Med. 2009 May; 84(5):565. PMID: 19704187.
    View in: PubMed
  25. Redig A. Volunteers and the great unknown: interview with clinical-trial participants. Virtual Mentor. 2009 Apr 01; 11(4):331-4. PMID: 23195068.
    View in: PubMed
  26. Redig AJ, Sassano A, Majchrzak-Kita B, Katsoulidis E, Liu H, Altman JK, Fish EN, Wickrema A, Platanias LC. Activation of protein kinase C{eta} by type I interferons. J Biol Chem. 2009 Apr 17; 284(16):10301-14. PMID: 19211565; PMCID: PMC2667717.
  27. Redig A. Finding the line: physicians, pharma, and drug development. Acad Med. 2009 Feb; 84(2):228-9. PMID: 19174673.
    View in: PubMed
  28. Redig AJ, Platanias LC. Protein kinase C signalling in leukemia. Leuk Lymphoma. 2008 Jul; 49(7):1255-62. PMID: 18604714.
    View in: PubMed
  29. Dolniak B, Katsoulidis E, Carayol N, Altman JK, Redig AJ, Tallman MS, Ueda T, Watanabe-Fukunaga R, Fukunaga R, Platanias LC. Regulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2. J Biol Chem. 2008 May 02; 283(18):12034-42. PMID: 18299328; PMCID: PMC2335346.
  30. Altman JK, Yoon P, Katsoulidis E, Kroczynska B, Sassano A, Redig AJ, Glaser H, Jordan A, Tallman MS, Hay N, Platanias LC. Regulatory effects of mammalian target of rapamycin-mediated signals in the generation of arsenic trioxide responses. J Biol Chem. 2008 Jan 25; 283(4):1992-2001. PMID: 18048359.
    View in: PubMed
  31. Redig AJ, Platanias LC. The protein kinase C (PKC) family of proteins in cytokine signaling in hematopoiesis. J Interferon Cytokine Res. 2007 Aug; 27(8):623-36. PMID: 17784814.
    View in: PubMed
  32. Sassano A, Katsoulidis E, Antico G, Altman JK, Redig AJ, Minucci S, Tallman MS, Platanias LC. Suppressive effects of statins on acute promyelocytic leukemia cells. Cancer Res. 2007 May 01; 67(9):4524-32. PMID: 17483369.
    View in: PubMed
  33. Yoon P, Giafis N, Smith J, Mears H, Katsoulidis E, Sassano A, Altman J, Redig AJ, Tallman MS, Platanias LC. Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL-expressing cells. Mol Cancer Ther. 2006 Nov; 5(11):2815-23. PMID: 17121928.
    View in: PubMed
  34. Redig AJ. Distributing drug samples in a free clinic: a personal or policy decision? Virtual Mentor. 2006 Nov 01; 8(11):729-34. PMID: 23241484.
    View in: PubMed
  35. Redig AJ. Of men and microbes: physicians and the ethics of epidemics. Virtual Mentor. 2006 Apr 01; 8(4):194-6. PMID: 23241614.
    View in: PubMed
  36. Redig AJ. A piece of my mind. Jigsaw. JAMA. 2006 Jan 25; 295(4):363-4. PMID: 16434620.
    View in: PubMed
  37. Redig AJ, Besselsen DG. Detection of rodent parvoviruses by use of fluorogenic nuclease polymerase chain reaction assays. Comp Med. 2001 Aug; 51(4):326-31. PMID: 11924790.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For demographic and contact information changes only, HMS/HSDM faculty should contact Human Resources at human_resourceshms.harvard.edu.
Redig's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_